Answers are grounded in this paper and cite their sources.
Analyzes the correlation between synuclein gamma and angiogenesis in colon cancer, suggesting new therapy options.
Background Colorectal cancer is one of the leading causes of death worldwide. Synuclein gamma (SNCG) is undetectable in normal tissue or benign lesions and shows high expression in cancer. This stage-specific expression suggested that this protein may be linked to the process of tumorigenesis. Endoglin (CD105), modulates angiogenesis by controlling of endothelial cell proliferation. Aim of the work To analyze the immunohistochemical expression of SNCG in tumorigensis phases of colon cancer and its correlation with angiogensis and clincopathological features. Materials and methods By immunohistocemical method, the expression of SNCG and endoglin was examined in studied biopsies (six normal colon biopsies as a control group, 10 adjacent nontumorous tissues, 10 adenomas, 30 adenocarcinomas, and six metastatic deposits in lymph nodes). Results The increased expression of SNCG was significantly associated with increased mean vascular count and both increased with the transition from adenoma to carcinoma groups ( r =0.796, P <0.001). Conclusion Here we report up-regulation of SNCG and endoglin protein expression with the transition from adenoma to carcinoma, and this indicates their interactive involvement in the pathogenesis of these tumors. Our findings offer opportunities for targeted therapy of cancer colon using SNCG inhibitors.
No takes yet. Share an insight, caveat, or question.
Elsers et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: